Glenn Prestwich at University of Utah to Speak at Modern Drug Summit Oct 24-26, 2012 in Philadelphia
Glenn D. Prestwich, Presidential Professor, Director of Therapeutic Biomaterials Center, and Special Presidential Assistant for Faculty Entrepreneurism of Medicinal Chemistry at the University of Utah Will Give a Plenary Keynote Presentation at the 8th Modern Drug Discovery & Development Summit (October 24-26, 2012 in Philadelphia, PA)
- (1888PressRelease) September 27, 2012 - Glenn D. Prestwich, Presidential Professor, Director of Therapeutic Biomaterials Center, and Special Presidential Assistant for Faculty Entrepreneurism of Medicinal Chemistry at the University of Utah Will Give a Plenary Keynote Presentation on "Biomaterials for Regenerative Medicine: From Bench to Business" at the 8th Modern Drug Discovery & Development Summit (October 24-26, 2012 in Philadelphia, PA)
Dr. Glenn Prestwich will describe the entrepreneurial ecosystem at the University of Utah as well as describe a case study for commercialization of a university technology in the area of regenerative medicine.
Clinical biomaterials for regenerative medicine. Injectable and biocompatible vehicles for delivery, retention, growth, and differentiation of progenitor cells are needed for cell therapy. Dr. Glenn Prestwich and his lab have created a synthetic extracellular matrix (sECM) from hyaluronic acid (HA) that affords highly reproducible, manufacturable, approvable, and affordable biomaterials. The technology is being commercialized in three fields of use: human medical devices, cell therapy and research tools for 3-D cell culture, and veterinary wound care and adhesion prevention.
Dr. Glenn D. Prestwich is a Presidential Professor of Medicinal Chemistry and Special Presidential Assistant for Faculty Entrepreneurism at the University of Utah, and he leads the University's Entrepreneurial Faculty Scholars program. His university research programs include (i) new reagents for lipid signaling in cell biology and cancer treatment, (ii) biomaterials for wound repair, cell therapy, tissue engineering, scar-free healing, and toxicology and xenograft models, and (iii) sulfated glycosaminoglycan analogs as inflammation modulators for clinical use.
From these technologies, he co-founded seven start-up companies, including Echelon Biosciences, Inc. (lipid signaling), Carbylan BioSurgery, Inc. (medical devices), Sentrx Animal Care, Inc. (veterinary wound care), Glycosan BioSystems, Inc. (cell therapy and research tools), and GlycoMira Therapeutics, Inc. (anti-inflammatory glycosaminoglycan drugs). He is also President & CEO of Metallosensors, Inc. (real-time mercury detection systems). He received the Governor's Medal for Science and Technology for 2006, the 1998 Paul Dawson Biotechnology Award and the 2008 Volwiler Research Award of the AACP, the 2010 University of Utah Distinguished Scholarly and Creative Research Award, and the 2010 "Rooster Prize" of the International Society for Hyaluronan Science.
GTC's 8th Modern Drug Discovery and Development Summit features a plenary keynote session followed by five parallel tracks:
• 9th Stem Cell Research and Therapeutics Conference
• 7th Assay and Drug Discovery Technologies Conference
• 4th Translational Medicine Conference
• 3rd Pharmacokinetics and Pharmacodynamics Conference
• Biotechnology Transfer and Commercialization Conference
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam